Stock ARCH ARCH BIOPARTNERS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Arch Biopartners Inc. Toronto S.E.

Equities

ARCH

CA03938C1041

Market Closed - Toronto S.E.
Other stock markets
 11:54:44 2024-07-15 EDT 		5-day change 1st Jan Change
1.625 CAD +0.31% Intraday chart for Arch Biopartners Inc. -1.52% +9.80%
06-27 Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product MT
06-27 Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product
MT
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
AQ
Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product
CI
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial
MT
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
AQ
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
CI
Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Arch Biopartners Inc. - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI
MT
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
MT
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
CI
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide
MT
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury
CI
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide
MT
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
CI
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACHFF Stock
  4. ARCH Stock
  5. News Arch Biopartners Inc.